moxifloxacin has been researched along with Communicable Diseases, Emerging in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bajaksouzian, S; Biek, D; Critchley, IA; Good, CE; Jacobs, MR; Jones, RN; Sader, HS; Windau, AR | 1 |
| Acharya, NR; Borkar, DS; Lalitha, P; Lietman, TM; Mascarenhas, J; McLeod, SD; Oldenburg, CE; Porco, TC; Rajaraman, R; Ravindran, M; Ray, KJ; Srinivasan, M; Zegans, ME | 1 |
| del Mar Gamboa-Coronado, M; López-Ureña, D; Montoya-Ramírez, M; Quesada-Gómez, C; Rodríguez, C; Rodríguez-Cavallini, E; Somogyi, T | 1 |
1 trial(s) available for moxifloxacin and Communicable Diseases, Emerging
| Article | Year |
|---|---|
Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India.
Topics: Anti-Bacterial Agents; Aza Compounds; Communicable Diseases, Emerging; Cornea; Corneal Ulcer; Double-Blind Method; Drug Resistance, Bacterial; Drug Therapy, Combination; Eye Infections, Bacterial; Fluoroquinolones; Glucocorticoids; Humans; India; Microbial Sensitivity Tests; Moxifloxacin; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2013 |
2 other study(ies) available for moxifloxacin and Communicable Diseases, Emerging
| Article | Year |
|---|---|
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Communicable Diseases, Emerging; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; United States | 2010 |
Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaks.
Topics: Anti-Bacterial Agents; Clindamycin; Clostridioides difficile; Clostridium Infections; Communicable Diseases, Emerging; Costa Rica; Cross Infection; Diarrhea; Disease Outbreaks; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Enterocolitis, Pseudomembranous; Fluoroquinolones; Genes, Bacterial; Genotype; Hospitals; Humans; Microbial Sensitivity Tests; Molecular Typing; Moxifloxacin; Ribotyping; Time Factors; Vancomycin | 2016 |